The Front Room — a clinical regulatory commons
RSS
← Back to The Docket
MAY 15 2026
APPROVED · 137 DAYS AGO

Genentech — Tecentriq (atezolizumab) $RHHBY

for muscle-invasive bladder cancer

BLA

FDA approved Genentech's Tecentriq for adjuvant treatment of muscle-invasive bladder cancer using ctDNA-guided therapy.

About

Muscle-invasive bladder cancer is an aggressive disease where tumors grow into the bladder wall and can spread to other organs. Tecentriq is an antibody that blocks a protein called PD-L1, which cancer cells use to hide from the body's immune defenses. By unmasking the cancer, this drug may help the patient's own immune system find and attack the tumor cells.

Pivotal trial

NCT02792192 Phase 1/Phase 2 terminated NCT02792192

This Phase Ib/II study is designed to assess the safety, tolerability, pharmacokinetics, immunogenicity, patient reported outcomes (PROs), and preliminary anti-tumor activity of atezolizumab administered by intravenous (IV) infusion alone and in combination with intravesical BCG in high-risk NMIBC participants. The study will be conducted in following cohorts: Cohort 1A, Cohort 1B, Cohort 2, and Cohort 3

Source: ClinicalTrials.gov

Also in development

Share LinkedIn X Bluesky